Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05327647 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer

Study acronym: BicaBCa
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 18, 2025 (before its estimated September 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jul 1, 2025 to Sep 1, 2026v11
  2. Site details revised at 1 of 7 sitesv10
  3. Study sites revised (7)v9
  4. Re-verified, no change to tracked fieldsv8
  5. Primary completion date: Jul 1, 2024 to Jul 1, 2025v7 Show 4 more changesShow less
    • Study sites: 4 to 7
    • Eligibility criteria shortened, about 82 words
    • Study description expanded, about 78 words
    • Collaborators: 1 to 2
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 3 to 4v6
  2. Study sites: 2 to 3v5
  3. Study sites: 1 to 2v4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Jul 1, 2025 to Jul 1, 2024
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 1, 2022 to Jun 23, 2022
    v3
  5. Secondary endpoints: details revised at 2 of 5 entries
    • Study title shortened, about 1 word
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase II randomized controlled clinical trial comparing standard induction BCG versus bicalutamide and standard induction BCG among patients with non-muscle invasive bladder cancer.
Trial Details
NCT Number NCT05327647
Lead Sponsor CHU de Quebec-Universite Laval
Collaborators: Canadian Institutes of Health Research (CIHR), Cancer Research Society
Conditions
(from sponsor)		 Non-Muscle Invasive Bladder Cancer
Related terms Non-Muscle Invasive Bladder Neoplasms
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov